Following the recommendation of an expert panel in Japan's health ministry, the health minister will likely give his approval for the first CAR-T therapy in the country. Novartis' Kymriah therapy, which has already received approvals in other countries, will be the beneficiary of the recommendation. The Japanese government is also expected to approve a clinical trial that aims at testing whether Kymriah's immunotherapy can prevent or treat certain types of cancer.
Following the recommendation of an expert panel in Japan's health ministry, the health minister will likely give his approval for the first CAR-T therapy in the country. Novartis' Kymriah therapy, which has already received approvals in other countries, will be the beneficiary of the recommendation. The next step will be the process of pricing the therapy under the public health insurance system.